Beone Medicines Ltd. - American Depositary Shares (ONC) closed at $416.54 on November 13, 2026, up 0.1% from the previous close, on volume of 182,988 shares (30-day average 422,224).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Seagull With Put Spread | 20-Nov-26330 P : 360 P : 420 C | 1,050 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
BeOne Medicines Ltd (6160) Gets a Buy from Daiwa
TipRanks (Tue, 10-Nov 8:05 PM ET)
CLSA Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
TipRanks (Mon, 9-Nov 7:35 PM ET)
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
Business Wire (Thu, 5-Nov 6:00 AM ET)
Business Wire (Wed, 4-Nov 9:13 AM ET)
BeOne Medicines to Present at the Jefferies Global Healthcare Conference
Business Wire (Tue, 3-Nov 6:01 AM ET)
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Business Wire (Sat, 24-Oct 4:15 AM ET)
Business Wire (Fri, 23-Oct 10:15 AM ET)
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
Business Wire (Thu, 22-Oct 6:01 AM ET)
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
Business Wire (Mon, 19-Oct 6:00 AM ET)
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
Business Wire (Tue, 1-Sep 6:00 AM ET)
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.
As of November 13, 2026, ONC stock price climbed to $416.54 with 182,988 million shares trading.
ONC has a beta of 0.48, meaning it tends to be less sensitive to market movements. ONC has a correlation of 0.02 to the broad based SPY ETF.
ONC has a market cap of $47.12 billion. This is considered a Large Cap stock.
Last quarter Beone Medicines Ltd. - American Depositary Shares reported $2 billion in Revenue and $4.59 earnings per share. This beat revenue expectation by $132 million and exceeded earnings estimates by $2.62.
The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, CGGO, CGGE, CGNG.
ONC has underperformed the market in the last year with a return of +13.1%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ONC shares. However, ONC has outperformed the market in the last 3 month and 2 week periods, returning +17.0% and +12.5%, while SPY returned -2.8% and -0.2%, respectively. This indicates ONC has been having a stronger performance recently.
ONC support price is $404.76 and resistance is $427.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.
